Raymond James Financial Services Advisors Inc. Buys 506 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Raymond James Financial Services Advisors Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWRGet Rating) by 2.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 19,382 shares of the biotechnology company’s stock after buying an additional 506 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Arrowhead Pharmaceuticals were worth $641,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Strs Ohio raised its stake in Arrowhead Pharmaceuticals by 3.0% in the 2nd quarter. Strs Ohio now owns 40,700 shares of the biotechnology company’s stock worth $1,433,000 after purchasing an additional 1,200 shares in the last quarter. B. Riley Wealth Management Inc. acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $1,859,000. Swiss National Bank raised its stake in Arrowhead Pharmaceuticals by 0.6% in the 2nd quarter. Swiss National Bank now owns 236,100 shares of the biotechnology company’s stock worth $8,313,000 after purchasing an additional 1,300 shares in the last quarter. AlphaCrest Capital Management LLC acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $677,000. Finally, Oak Ridge Investments LLC raised its stake in Arrowhead Pharmaceuticals by 51.9% in the 2nd quarter. Oak Ridge Investments LLC now owns 55,768 shares of the biotechnology company’s stock worth $1,964,000 after purchasing an additional 19,047 shares in the last quarter. Institutional investors own 65.46% of the company’s stock.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,200 shares of the business’s stock in a transaction that occurred on Monday, January 9th. The shares were sold at an average price of $30.00, for a total transaction of $96,000.00. Following the sale, the director now directly owns 28,950 shares of the company’s stock, valued at approximately $868,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Martin Javier San sold 19,500 shares of the stock in a transaction on Monday, November 21st. The shares were sold at an average price of $29.99, for a total transaction of $584,805.00. Following the completion of the sale, the insider now directly owns 91,500 shares in the company, valued at $2,744,085. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director William D. Waddill sold 3,200 shares of the company’s stock in a transaction on Monday, January 9th. The shares were sold at an average price of $30.00, for a total transaction of $96,000.00. Following the sale, the director now directly owns 28,950 shares in the company, valued at approximately $868,500. The disclosure for this sale can be found here. Insiders have sold 109,966 shares of company stock valued at $4,050,435 in the last ninety days. 3.20% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Trading Up 3.7 %

Shares of Arrowhead Pharmaceuticals stock opened at $33.92 on Wednesday. The firm has a market capitalization of $3.60 billion, a PE ratio of -20.19 and a beta of 1.26. The firm’s 50 day moving average is $33.89 and its 200 day moving average is $36.51. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $26.81 and a 1 year high of $56.25.

Arrowhead Pharmaceuticals (NASDAQ:ARWRGet Rating) last announced its quarterly earnings results on Monday, November 28th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.24). Arrowhead Pharmaceuticals had a negative net margin of 71.01% and a negative return on equity of 40.23%. The company had revenue of $31.58 million for the quarter, compared to the consensus estimate of $107.60 million. As a group, research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -0.86 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Piper Sandler dropped their price objective on shares of Arrowhead Pharmaceuticals from $64.00 to $55.00 in a research note on Monday, January 9th. SVB Leerink dropped their target price on shares of Arrowhead Pharmaceuticals from $33.00 to $31.00 and set a “market perform” rating for the company in a research report on Tuesday, November 29th. Jefferies Financial Group dropped their target price on shares of Arrowhead Pharmaceuticals from $92.00 to $75.00 and set a “buy” rating for the company in a research report on Tuesday, November 29th. HC Wainwright dropped their target price on shares of Arrowhead Pharmaceuticals from $110.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, December 6th. Finally, Chardan Capital dropped their target price on shares of Arrowhead Pharmaceuticals from $82.00 to $60.00 in a research report on Tuesday, January 10th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.22.

Arrowhead Pharmaceuticals Profile

(Get Rating)

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.

Read More

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.